Bücher
Monographien
Übersichtsarbeiten
Buchkapitel
Veröffentlichungen in Fachzeitschriften
Abstracts/Kongress-Beiträge: Poster-Präsentationen/Poster-Diskussionen


Bücher
________________________________________________
Wolf E (Hrsg), Mauss S, Jäger H. Die antiretrovirale Behandlung der HIV-Erkrankung. Thieme Verlag, Stuttgart, 1999.

Monographien
________________________________________________
Wolf E., Jäger H, KIS - HIV Drugfinder. Antiretrovirale Therapie 2005.

Wolf E., Jäger H, KIS - HIV Drugfinder. Antiretrovirale Therapie 2004.

Hoffmann C, Wolf E., Jäger H, KIS – KIS OI Drugfinder. Opportunistische Infektio-nen bei HIV 2002.

Wolf E., Jäger H, KIS - HIV Drugfinder. Antiretrovirale Therapie 2001.

Wolf E., Jäger H, KIS - HIV Drugfinder. Antiretrovirale Therapie 1999.

Wolf E., Jäger H, KIS - HIV Drugfinder. Antiretrovirale Therapie 1998.

Wolf E., Jäger H, KIS - HIV Drugfinder. Antiretrovirale Therapie 1997

Übersichtsarbeiten
________________________________________________
Mauss S., Wolf E. Aktueller Stand der Therapie der HIV-Infektion (Antiretrovirale Therapie). Therapien bei AIDS. Loseblattsammlung der deutschen AIDS-Hilfe 1997.

Buchkapitel
________________________________________________
Wolf E, Jaeger H. Country case study – The German situation. In: Bartlett JG, Lange JMA, Whiteside A, Zuniga JM (Hrsg.). A decade of the HAART: Historical per-spectives and future directions. In Press

Wolf E. Resistenzen. In: Hoffmann, Rockstroh, Kamps (Hrsg.). HIV.Net 2005. Stein-häuser Verlag, Wuppertal-Beyenburg, 2005.

Wolf E. HIV Drug Resistance 2005. In: Hoffmann, Rockstroh, Kamps (Editors). Available at: http://hivmedicine.com/textbook/authors/wolf.htm

Wolf E. Resistenzen. In: Hoffmann, Kamps (Hrsg.). HIV.Net 2004. Steinhäuser Ver-lag, Wuppertal-Beyenburg, 2004.

Wolf E. Resistenzen. In: Hoffmann, Kamps (Hrsg.). HIV.Net 2003. Steinhäuser Ver-lag, Wuppertal-Beyenburg, 2003.

Wolf E, Gersbacher E, Pascucci R, Moser-Jünemann Ch, Jaegel-Guedes E., Jäger H. 3 Monate Efavirenz im klinischen Alltag – Effektivität und Toxizität in der Firt-line- und Salvage-Therapie. In: Brockmeyer N.H., Brodt R., Hoffmann K., Reimann G., Stücker M., P. Altmeyer (Hrsg.) HIV-Infekt. Springer-Verlag, Berlin – Heidel-berg, 2000.

Wolf E. Sequencing, Initialtherapie, Sekundär- und Folge- sowie Salvage-Therapie. In: Wolf E (Hrsg.), Mauss St, Jäger H. Die antiretrovirale Behandlung der HIV-Erkrankung. Thieme Verlag, Stuttgart, 1999.

Popescu M. u. Wolf E. HIV-1 RNA in fortgeschrittenen Stadien der HIV-1-Infektion. In: Jäger H. (Hrsg.) Virus Load und AIDS. Thieme Verlag, Stuttgart, 1997.

Wolf E, Wildegger A, Jäger H. Sample transportation on blue ice instead of dry ice - The impact on plasma HIV-1 RNA stability. In: Jäger H. (Hrsg.) Virus Load und AIDS. Thieme Verlag, Stuttgart, 1997

Fachzeitschriften
________________________________________________
Hill E, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, et al. Systematic review of clinical trials evaluating low doses of Stavudine as part of antiretroviral treatment. Expert Opin Pharmacother. 2007, 8 (5): 679-88

Hoffmann C, Wolf E, Wyen C, et al. AIDS-associated Burkitt or Burkitt-like lym-phoma: Short intensive polychemotherapy is feasible and effective. Leukemia & Lymphoma 2006, 47(9):1872-1880*

Fehr JS, Nicca D, Sendi P, Wolf E, et al. Starting or changing therapy-a prospective study exploring antiretroviral decision-making. Infection 2005, 33(4): 249-256 *

Wolf E, Hoffmann C, Procaccianti M, et al. Long-term consequences of treatment interruptions in chronically HIV-1-infected patients. Eur J Med Res 2005; 10: 56-62. Abstract: http://amedeo.com/lit.php?id=15817423

Hoffmann C, Tiemann M, Schrader C, Wolf E, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immuno-phenotyping. Blood 2005; 106: 1762-9. Epub 2005 May 19. Abstract: http://amedeo.com/lit.php?id=15905193

Fehr JS, Nicca D, Sendi P, Wolf E, et al. Swiss HIV Cohot Study. Starting or chang-ing therapy - a prospective study exploring antiretroviral decision-making. Infection 2005; 33: 249-56. Abstract: http://amedeo.com/lit.php?id=16091895

Hoffmann C, Chow KU, Wolf E, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin´s disease. Br J Haematol 2004; 125: 455-62. Abstract:
http://amedeo.com/lit.php?id=15142115

Mauss S, Scholten S, Wolf E, et al. A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir. HIV Med 2004; 5: 15-7. Abstract: http://amedeo.com/lit.php?id=14731164

Hoffmann C, Wolf E, Fatkenheuer G, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003; 17: 1521-9. Abstract: http://amedeo.com/lit.php?id=12824790

Mauss S, Corzillius M, Wolf E, et al. Risk factors for the HIV-associated lipodystro-phy syndrome in a closed cohort of patients after 3 years of antiretroviral treat-ment. HIV Med 2002; 3: 49-55. Abstract: http://amedeo.com/lit.php?id=12059951

Hoffmann C, Tabrizian S, Wolf E, et al. Survival of AIDS Patients with Primary Cen-tral Nervous System Lymphoma Is Dramatically Improved by HAART-Induced Immune Recovery. AIDS 2001, 15: 2119-2127.

Wintergerst U, Kurowski M, Rolonski B, Müller M, Wolf E, Jaeger H, Belohradsky BH. Use of Saliva Specimens for Monitoring Indinavir Therapy in Human Immunode-ficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy 2000, Sept, Vol. 44, No.9: 2572-2574.

Mauss S, Wolf E, Hans J. Changing incidence of mycobacterial diseases in German patients with HIV infection. AIDS Read 1999; 9: 386, 391-2. Abstract: http://amedeo.com/lit.php?id=12737129

Mauss S, Wolf E, Moser-Jünemann Ch, Jäger H. Reversal of protease inhibitor re-lated visceral abdominal fat accumulation with recombinant human growth hor-mone. Annals.of Internal Medicine 1999. 131: No 4.

Mauss S, Wolf E, Moser-Jünemann Ch, Jäger H. Reversal of Visceral Abdominal Fat Accumulation Associated with the Use of HIV-Protease Inhibitors after Treatment with recombinant Human Growth Hormone. Annals.of Internal Medicine 1999, 2: 313f.

Wintergerst U, Rolinski B, Sölder B, Bogner JR, Wolf E, Jäger H, Roscher AA, Be-lohradsky BH. Lack of Absorption of Didanosine after Rectal Administration in Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy 1999, March : 699-701

Dietrich U, Raudonat I, Wolf E, Jäger H, Husak R, Orfanos CE, Knickmann M, Knechten H, von Briesen H, Ruppach H, Immelmann A. Indication for increasing, prevalence oft resistance mutations for protease inhibitors in therapy-naive HIV-1-positive German patients. AIDS 1999, 13: 2304-2305

Mauss S, Wolf E, Jäger H. Impaired Glucose Tolerance in HIV-Positive Patients Re-ceiving and Those Not Receiving Protease Inhibitors. Annals of Internal Medicine 1999, 2: 162-163

Jäger H, Wolf E, Hammel G, Zwingers Th, Goetzenich A, Knechten H. Therapie-standard wird im Alltag nur mäßig umgesetzt. Deutsches Ärzteblatt 1999, 3A: 108 - 112.

Poppinger J, Wolf E, Morbach K, Pascucci R, Virgin G, Jaegel-Guedes E, Jäger H. Stavudine plus lamivudine versus zidovudine plus lamivudine in antiretroviral-naive HIV-positive patients. Antiretroviral Therapy 1997 2 (Supplement 3): 109 - 111.

Dietrich U, Ruppach H, Gehring S, Knechten H, Knickmann M, Jäger H, Wolf E, Hu-sak R, Orfanos CE, Brede HD, Rübsamen-Waigmann H, von Briesen H. Large proportion of non-B HIV-1 subtypes and presence of zidovudine r esistance muta-tions among German seroconvertors. AIDS 1997; 12: 1532-1533.*

Tiller FW, Wolf E, Jägel-Guedes E, Jäger H. Application of Q-NASBATM for determi-ning HIV-1 Viral Load in Human Plasma. Clinical Laboratory - Virology. 1995; 41: 769 - 772.

Abstracts/Kongress-Beiträge: Poster-Präsentationen/Poster-Diskussionen
________________________________________________
Koegl C, Wolf E, Jessen H, Schewe K, Rausch M, Goelz J, Goetzenich A, Knechten H, Jaeger H and the Prime-DAG and Ac-DAG Study Group. No Benefit from Early Treatment in Primary HIV-Infection. 14th Conference on Retroviruses and Oppor-tunistic Infections. Los Angeles. 25.-28. Februar 2007. Abstrakt 125LB

Koegl C, Wolf E, Eberhard A, Jaegel-Guedes E, Jaeger H. Fosamprenavir/ritonavir (FPV/r): decrease of liver enzymes in patients co-infected with hepatitis C. Eighth International Congress on Drug Therapy in HIV Infection. Glasgow. 12.-16. No-vember 2006. Abstrakt P108

Wolf E, Gunturu G, Koegl C, Jaegel-Guedes E, Jaeger H. Tenofovir (TDF) versus non-TDF-containing ART: renal safety in daily practice. Eighth International Con-gress on Drug Therapy in HIV Infection. Glasgow. 12.-16. November 2006. Ab-strakt P153

Vogel M, Wolf E, Ummard K, Koegl C, Wasmuth J-C, Bicim G, Moll A, Jaeger H, Rockstroh JK. Injection site reactions (ISR) and success of HAART influence con-tinued use of enfuvirtide (T20). Eighth International Congress on Drug Therapy in HIV Infection. Glasgow. 12.-16. November 2006. Abstrakt P183

Wolf E, Koegl C, Theobald T, Jaegel-Guedes E, Jaeger H. Nevirapine-associated hepatotoxicity: no increased risk for females or high CD4 count in a single-centre HIV cohort. 46th annual ICAAC. San Francisco. 27.-30. September 2006. Abstrakt H-1063

Koegl C, Wolf E. Jessen H, Schewe K, Rausch M, Goelz J, Goetzenich A, Knechten H, Jaeger H, and the Prime-DAG and Ac-DAG Study Group. XVI International AIDS Conference. Toronto. 13.-18. August 2006. Abstrakt MOPE0060

Jaeger H, Wolf E, Jaegel-Guedes E, Chantratita W, Schumacher W. HIV real-time PCR assay COBAS AmpliPrep/COBAS TaqMan HIV-1 test in comparison to the Bayer bDNA assay versant HIV-1 RNA v3.0 and the Roche COBAS amplicor HIV monitor test v1.5. XVI International AIDS Conference. Toronto. 13.-18. August 2006. Abstrakt MOPE0156

Wolf E, Laubereau B, Gunturu G, Koegl C, Jaegel-Guedes E, Jaeger H. Electronic diaries: a new tool to measure social factors, clinical conditions, and health-related quality of life (HRQL) in HIV-patients on HAART. XVI International AIDS Confer-ence. Toronto. 13.-18. August 2006. Abstrakt TUPE0660

Goelz J, Wolf E, Moll A, Koegl C, Jaeger H. Single agent HAART with lopinavir/r (LPV/r) in ART-naive and pre-treated HIV-1-infected patients. XVI International AIDS Conference. Toronto. 13.-18. August 2006. Abstrakt THPE0134

Vogel M, Wolf E, Ummard K, Kögl C, Wasmuth J-C, Däumer M, Kupfer B, Kaiser R, Moll A, Jäger H, Rockstroh JK. Die Wertigkeit des genotypischen Interpretations-systems Virco TYPE HIV-1 auf das virologische Ansprechen bei Patienten mit 3-Klassen-Versagen. 11. Münchner AIDS Tage. München. 3.-5. Februar 2006. S. 43-45

Wolf E, Walter H, Eckerlein B, Koegl C, Jaegel-Guedes E, Jaeger H. Development of De Novo PI-Resistance in Lopinavir/Ritonavir-Monotherapy. 3rd IAS Confer-ence on Pathogenesis and Treatment. Rio de Janeiro. 24.-27. Juli 2005. Abstrakt WePe4.4C08

Koegl C, Wolf E, Jessen H, Schewe K, Rausch M, Goelz J, Knechten H, Jaeger H. Virus control after early treatment of primary HIV-infection. 10. Deutscher und 16. Österreichischer AIDS-Kongress. Wien. 1.-4. Juni 2005. Abstrakt V8

Wolf E, Kaliebe T, Ranneberg B, Koegl C, Schewe K, Jaegel-Guedes E, Jaeger H. Renal safety of Tenofovir (TDF) in clinical practice – a pooled analysis of two Ger-man cohorts. 10. Deutscher und 16. Österreichischer AIDS-Kongress. Wien. 1.-4. Juni 2005. Abstrakt P154

Koegl C, Wolf E, Ruemmelein N, Morbach K, Buchberger A, Wandel J, Jaeger H. Large Nevirapine cohort: 7% discontinuation due to Hepatotoxicity. XV. Internatio-nal AIDS Conference. Bangkok. 11.-16. Juli 2004. Abstract WePeB5933

Jaegel-Guedes E, Wolf E, Ruemmelein N, Postel N, Koegl C, Buchberger A, Wandel J, Weisser S, Jaeger H. Incidence of Tenofovir-related nephrotoxicity in a large outpatient cohort. XV. International AIDS Conference. Bangkok. 11.-16. Juli 2004. Abstract WePeB5937

Postel N, Wolf E, Koegl C, Buchberger A, Ruemmelein N, Wandel J, Jaegel-Guedes E, Jaeger H. Anti-HBV Vaccination in HIV-Infection: Successful only with CD4 cell count >500/µl combined with a viral load below 1000 cps/ml. XV. International AIDS Conference. Bangkok. 11.-16. Juli 2004. Abstract MoPeB3330

Wolf E, Koegl C, Hoffmann C, Ruemmelein N, Postel N, Jaegel-Guedes E, Jaeger H. Low dose stavudine: less side effects but as effective as standard dose. XV. In-ternational AIDS Conference. Bangkok. 11.-16. Juli 2004. Abstract WePeB5861

Wolf E, Ruemmelein N, Hoffmann C, Buchberger A, Kuschak D, Kögl C, Tiller FW, Postel N, Jaegel-Guedes E, Jaeger H. Week 2 – Nevirapine (NVP) plasma levels are associated with NVP-related toxicity. XV. International AIDS Conference. Bangkok. 11.-16. Juli 2004. Abstract TuPeB4640

Ruemmelein N, Wolf E, Koegl C, Wadel J, Jaegel-Guedes E, Jaeger H. Primary HIV-infection: lower viral setpoint in early treated patients. International AIDS Con-ference. Bangkok. 11.-16. Juli 2004. Abstract TuPeB4592

Jaeger H, Jessen H, Goetzenich A, Koegl C, Schewe K, Rausch M, Wolf E, Goelz J, Knechten H. Primary HIV-infection: clinical symptoms are correlated with early outcome in non-treatment group. XV. International AIDS Conference. Bangkok. 11.-16. Juli 2004. Abstract TuPeB4590

Koegl C, Buchberger A, Morbach K, Postel N, Ruemmelein N, Wolf E, Wandel J, Eberhard A, Jaegel-Guedes E, Jaeger H. Lipids or Virus. Atazanavir as effective as Lopinavir. XV. International AIDS Conference. Bangkok. 11.-16. Juli 2004. Abs-tract TuPeB4557

Wolf E, Laubereau B, Wandel G, Gunturu G, Ruemmelein N, Buchberger A, Jaegel-Guedes E, Jaeger H. Electronic diaries: Daily assessment of quality of life (QoL) shows high depression in HIV/AIDS. XV. International AIDS Conference. Bang-kok. 11.-16. Juli 2004. Abstract MoPeD3884

Hoffmann C, Wolf E, Faetkenheuer G, Wyen C, Stellbrink HJ, van Lunzen J, Stoehr A, Plettenberg A, Jaeger H, Noppeney R, Hoelzer D, Horst HA. The short and in-tensive B-all protocol is a highly effective regimen in patients with AIDS-associated Burkitt or Burkitt-like Lymphoma. 11th Conference on Retroviruses and Opportun-istic Infections. San Francisco. 8.-11. Februar 2004. Abstract Nr. 787

Postel N, Wolf E, Ruemmelein N, Buchberger A, Jaegel-Guedes E, Jaeger H. Uni-versal protease associated mutations (UPAMS) are responsable for Lopina-vir/Ritonavir (LPV/R) - based HAART-failure – analysis of 79 patients based on genotyping. 9th European AIDS Conference. Warschau. 25.-29. Oktober 2003. Abstract Nr. 3.4/9

Mauss S, Holm S, Wolf E, Kuhlmann B, Bellmunt A, Jaeger H, Berger F, Schmutz G. Tenofovir in clinical practice – first, second, third line? 9th European AIDS Confe-rence. Warschau. 25.-29. Oktober 2003. Abstract Nr. 7.4/17

Koegl C, Wolf E, Postel N, Buchberger A, Ruemmelein N, Jaegel-Guedes E, Jaeger H. Low dose Stavudine: As effective as standard dose but less side effects. 9th European AIDS Conference. Warschau. 25.-29. Oktober 2003. Abstract Nr. 9.8/5

Fehr J, Nicca D, Spirig R, Wagels T, Kiss A, Bregenzer T, Vernazza P, Sendi P, Wolf E, Jäger H, Battegay M and the Swiss HIV Cohort Study. Starting or chang-ing HAART: readiness of patients. 9th European AIDS Conference. Warschau. 25.-29. Oktober 2003. Abstract Nr. 10.1/3

Hoffmann C, Corzillius M, Wolf E, Fätkenheuer G, Woehrmann A, Stoehr A, Pletten-berg A, Lorenzen T, Stellbrink HJ, van Lunzen J, Jäger H, Horst HA. AIDS-assoziierte Burkitt-Lymphome – Erfahrungen mit dem B-ALL-Protokoll. 9. Deut-scher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abs-tract Nr. 22

Postel N, Rümmelein N, Wolf E, Gersbacher E, Buchberger A, Kögl C, Morbach K, Hoffmann C, Jägel-Guedes E, Jäger H. Erfahrungen mit Lopinavir/ritonavir (LPV/r) bei 300 HIV-infizierten Patienten über einen Zeitraum von 12 Monaten. 9. Deut-scher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abs-tract Nr. 62

Koegl C, Gersbacher E, Buchberger A, Wolf E, Ruemmelein N, Postel N, Morbach K, Jagel-Guedes E, Jaeger H. Klassenbester? PI, NNRTI, NRTI im Vergleich bei therapie-naiven Patienten. 9. Deutscher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abstract Nr. 68

Jaeger H, Koegl C, Wolf E, Jessen H, Schewe C, Goelz J, Hoffmann C, Fenske S, Knechten H. Prime DAG – erste Ergebnisse zu 91 Patienten mit primärer HIV-Infektion. 9. Deutscher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abstract Nr. 83

Ruemmelein N, Wolf E, Hoffmann C, Koegl C, Jaegel-Guedes E, Jaeger H. Anti-retrovirale Therapie (ART) und Strukturierte Therapieunterbrechungen (STI) bei der primären HIV-Infektion (PHI). 9. Deutscher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abstract Nr. 85

Wolf E, Hoffmann C, Ruemmelein N, Buchberger A, Kuschak D, Koegl C, Tiller FW, Postel N, Jaegel-Guedes E, Jaeger H. Therapeutisches Drug-Monitoring (TDM) von Nevapirin (NVP) und das Auftreten NVP-assoziierter Nebenwirkungen. 9. Deutscher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abstract Nr. 118

Mauss S, Scholten S, Wolf E, Berger F, Schmutz G, Jaeger H, Kurowski M, Rock-stroh JK. Kann Ritonavir 200 mg bid die Interaktion von Lopinavir und Amprenavir verhindern? 9. Deutscher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abstract Nr. 125

Postel N, Wolf E, Buchberger A, Rümmelein N, Weisser S, Jägel-Guedes E, Jäger H. Impferfolg gegen Hepatitis B-Virus bei HIV-Infizierten ist abhängig von Viruslast und CD4-Zellzahl. 9. Deutscher und 14. Österreichischer AIDS-Kongress. Ham-burg. 14.-17. Mai 2003. Abstract Nr. 161

Hoffmann C, Wolf E, Jägel-Guedes E, Wildegger A, Jäger H. Persistenz genotyppi-scher Resistenzmutationen nach Transmission multiresistenter Viren. 9. Deut-scher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abs-tract Nr. 191

C. Hoffmann*, E. Wolf, G. Fätkenheuer, T. Buhk, A. Stoehr, A. Plettenberg, T. Lo-renzen, H.J. Stellbrink, U. Siebert, K. Schewe, J. van Lunzen, H.A. Horst, H. Jä-ger. AIDS-Related Lymphoma (ARL): Outcome Is Strongly Predicted by Efficacy of Highly Active Antiretroviral Therapy (HAART). 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Feb 24-27, 2002, Poster # 619 W.

Wolf, E., Gersbacher, E., Schardt, J., et. al. Long-term effects of treatment interrup-tions (TI): 18-month evaluation of a controlled trial in > 300 HIV+ patients. 41th In-terscience Conference on Antimicrobial Agents and Chemotherapy, Dec. 16-19, 2001, abstract 1910.

Hoffmann C, Mayer W, Wolf E, et al. Enhancement of HIV Specific Immune Re-sponse during Structured Treatment Interruptions (STI) in Chronic HIV-Infection Depends on Baseline Viral Load. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, Dec. 16-19, 2001, abstract 1910.

Wolf E, Hoffmann C, Gersbacher E , Schardt J , Mueller S, Mosthaf F, Ulmer A, Pro-caccianti M, Jägel-Guedes E, Jäger H. Langzeiteffekte von Therapiepausen (TP): 18-Monats-Auswertung einer kontrollierten, prospektiven Studie an über 300 HIV-Patienten.8th German AIDS Conference July 4-7, 2001 Eur J Med Res 6 (Suppl I) 2001: 39.

Hoffmann C, Tabrizian S, Wolf E, Buhk T, Eggers C, Stellbrink HJ , Stoehr A, Plet-tenberg A, Horst HA , Jaegel-Guedes E, Jaeger H, Rosenkranz T. Survival of AIDS Patients with Primary Central Nervous System Lymphoma Is Dramatically Improved by HAART-Induced Immune Recovery. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Feb 4-8, 2001, Abstract-Nr. J19e/ Poster-Nr. 590.

Hoffmann C, Wolf E, Mueller S, Ulmer A, Procaccianti M, Mosthaf F, Schardt J, Ger-sbacher E, Moser-Juenemann C, Buchberger A, Jaegel-Guedes E, Jaeger H. Drug Holidays in HIV+ Patients – Clinical Issues. Fifth International Congress on Drug Therapy in HIV Infection, Oktober 22-26, 000, Glasgow, Poster/Abstract-Nr. 68.

Mauss S, Corzillius M, Wolf E, Schwenk A, Jaeger H, Goelz J, Knechten H, Adam A, Goetzenich A. Risk factors for HALS (HIV-associated lipodystrophy syndrome) in patients with uniform duration of ART. 2nd International Workshop on Adverse drug Reactions and Lipodystrophy in HIV, Toronto, 2000, Sept. 13-15. Poster/Abstract-Nr. P68.

Mauss S, Corzillius M, Wolf E, Schwenk A, Jaeger H, Goelz J, Knechten H, Adam A, Goetzenich A. Prevalence and Risk factors for the HIV-Associated Lipodystrophy Syndrome (HALS) in Patients Beiing 3 Years on ART. 40th Intersience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto, 2000, Sept. 17-20. Poster/Abstract-Nr. 1287

Hoffmann C, Jaegel-Guedes E, Wolf E, Gersbacher E, Mueller S, Pascucci R, Buchberger A, Moser-Juenemann C, Jaeger H. PI-sparing in ART-naive HIV+ pa-tients: Efficacy and Tolerability of d4T/ddI plus Efavirenz (EFV) vs d4T/ddI plus Abacavir (ABC). 13th International AIDS Conference, Durban, South Africa, July 9-14,2000, Poster/Abstract-Nr. WePeB4185.

Wolf E, Jaegel-Guedes E, Mueller S, Pascucci R, Moser-Juenemann C, Buchberger A, Hoffmann C, Jaeger H. Estradiol levels and lipodystrophy in HIV+ men. 13th In-ternational AIDS Conference, Durban, South Africa, July 9-14,2000, Poster/ Abstract-Nr. WePpB1382.

Jaegel-Guedes E, Richter D, Leiberich P, Lydtin D, Wolf E, Morbach K, Pascucci R, Buchberger A, Moser-Juenemann C, Jaeger H. Chronic fatigue – a growing prob-lem in ART- treated HIV+ patients. 13th International AIDS Conference, Durban, South Africa, July 9-14,2000, Poster/Abstract-Nr. WePeC4458.

Jaeger H, Wolf E, Schardt J, Ulmer A, Procaccianti M, Mosthaf F, Mueller S, Moser-Juenemann C, Pascucci R, Buchberger A, Hoffmann C, Jaegel-Guedes E. Drug Holidays (DH): Impact on VL, CD4 Cells and Clinical Outcome in HIV+ patients. 13th International AIDS Conference, Durban, South Africa, July 9-14,2000, Poster/Abstract-Nr. WePeB4207.

Jaegel-Guedes E, Wolf E, Gersbacher E, Lydtin D, Mueller S, Pascucci R, Moser-Juenemann C, Hoffmann C, Jaeger H. HU (hydroxyurea) vs PI, both combined with d4T+ddI, in ART- naive HIV+ patients. 13th International AIDS Conference, Durban, South Africa, July 9-14,2000, Poster/Abstract-Nr. ThPeB5060.

Jaeger H, Gersbacher E, Wolf E, Hoffmann C, Pascucci R, Moser-Juenemann C, Jaegel-Guedes E. Efavirenz (EFV) versus Nevirapine (NVP): Efficacy and effects on blood lipids in PI-sparing regimens. 13th International AIDS Conference, Dur-ban, South Africa, July 9-14,2000, Poster/Abstract-Nr. WePeB4182.

Hoffmann C, Jaegel-Guedes E, Wolf E, Gersbacher E, Pascucci R, Moser-Juenemann C, Jaeger H. PI to Efavirenz (EFV) switch effect on lipids in HIV-positive patients. 13th International AIDS Conference, Durban, South Africa, July 9-14,2000, Poster/Abstract-Nr. WePeB4185.

Wolf E, Gersbacher E, Buchberger A, Eckerlein B, Wildegger A, Tiller FW, Graebnitz F, Mueller S, Moser-Juenemann C, Pascucci R, Hoffmann C, Jaegel-Guedes E, Jaeger H. Genotypic antiretroviral resistance and clinical outcome: data from a community-based outpatient HIV practice. 13th International AIDS Conference, Durban, South Africa, July 9-14,2000, Poster/Abstract-Nr. TuPeB3281.

Mauss S, Corzillius M, Wolf E, Schwenk A, Jaeger H, Goelz J, Knechten H, Adam A, Goetzenich A. Risk factors for HALS (HIV-associated lipodystrophy syndrome) in patients with uniform duration of ART. 13th International AIDS Conference, Dur-ban, South Africa, July 9-14,2000, Poster/Abstract-Nr. ThPpB1486

Jaegel-Guedes E, Wolf E, Gersbacher E, Pascucci R, Moser-Jünemann Ch, Buchberger A, Jäger H. ddI/d4T plus hydroxyurea - An alternative to a PI-containing triple regimen in ART-naive HIV+ patients? 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, October 23-27,1999, Poster/Abstract-Nr. 563.

Jäger H, Pascucci R, Wolf E, Gersbacher E , Buchberger A, Moser-Jünemann Ch, Jaegel-Guedes E. PI-sparing in ART-naive HIV-Patients: D4T/DDI plus Efavirenz (EFV) vs. D4T/DDI plus Abacavir (ABC). 7th European Conference on Clinical As-pects and Treatment of HIV-Infection, Lisbon, Portugal, October 23-27,1999, Poster/Abstract-Nr. 562.

Kurowski M, Wintergerst U, Müller M, Rolinski B, Jäger H, Wolf E. Relation of saliva and plasma levels in patients treated with ritonavir and indinavir. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, October 23-27,1999, Poster/Abstract-Nr. 833.

Moser-Jünemann Ch, Wolf E, Pascucci R, Jaegel-Guedes E, Jäger H. Avascular necrosis of the femoral head in an HIV+man associated more likely with hyperlipi-demia than with corticoid treatment. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, October 23-27,1999, Poster/Abstract-Nr. 1075.

Dietrich U, Raudonat I, Knickmann M,Knechten H, Wolf E, Jaeger H, Husak R, von Briesen, Ruppach H, Immelmann A. Evidence for transmission of HIV-1 variants with resistance mutations for protease inhibitors in Germany. 7th European Con-ference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, Oc-tober 23-27,1999, Poster/Abstract-Nr. 1002.

Corzillius M., Schwenk A., Wolf E., Goetzenich A., Mauss S., Beckmann R., Jaeger H., Breuer P., Knechten H., Locher L., Adam A. Does phycisian assessment match patient perception of body changes in lipodystrophy? 7th European Con-ference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, Oc-tober 23-27,1999, Late-Breaker Abstract-Nr. 1220

Goetzenich M., Schwenk A., Corzillius M., Wolf E., Mauss S., Beckmann R., Jaeger H., Breuer P., Knechten H., Locher L., Adam A. Impact of lipodystrophy on quality of life. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, October 23-27,1999 Late-Breaker Abstract-Nr. 1211.

Wolf E, Gersbacher E, Buchberger A, Pascucci R, Moser-Jünemann Ch, Lydtin D, Jägel-Guedes E, Jäger H. Use of Ritonavir in Salvage Therapy. 39th ICAAC, San Francisco, 26. – 29. September 1999. Poster/Abstract I-212.

Wolf E, Jäger H., Gersbacher E, Pascucci R, Moser-Jünemann Ch, Jaegel-Guedes E. 3 Monate Efavirenz im klinischen Alltag – Effektivität und Toxizität in der Firt-line- und Salvage-Therapie. 7. Deutscher AIDS-Kongreß, Essen, 2. – 6. Juni 1999. NA 35.3, Abstract F1189.

Ronel J, Mitzdorf U., Wolf E., Jägel-Guedes E., Jäger H. Psychosoziale Korrelate der HIV-Krankheitsprogression. 7. Deutscher AIDS-Kongreß, Essen, 2. – 6. Juni 1999. NA 19.3, Abstract F1056.

Jäger H, Wolf E, Mosthaf F, Wildegger A, Ulmer A, Schuster D, Becker W. Clinical relevance of undetectable HIV RNA levels measured by the ultrasenisitive bDNA techology 3.0. 6th Conference on Retroviruses and Opportunistic Infections. Chi-cago, 13. Januar - 4. Februar 1999, Poster Präsentation (via Eva Wolf) Session 23/ Abstract-Nr. 174

Mauss St, Wolf E, Moser-Jünemann C, Jäger H. Successful treatment of PI-induced visceral abdominal fat accumulation with R-human growth hormone. 4th Interna-tional Congress on Drug Therapy in HIV Infection Glasgow, 8. - 12. November 1998, Poster/Abstract. AIDS 1999, 12: S53-S53.

Wolf E, Hammel G, Zwingers T, Goetzenich A, Knechten H, Jäger H. D4T plus 3TC or AZT plus 3TC - Viral Load Suppression After 12 Months. 12th World AIDS Con-ference. Genf, 28. Juni - 3. Juli 1998, Poster/Abstract-Nr. 32321

Wolf E, Mauss S, Pascucci R, Immelmann A, Dietrich U, Jägel-Guedes E, Jäger H. Impact of Protease Gene Mutations on Virological Response to Nelfinavir. 12th World AIDS Conference. Genf, 28. Juni - 3. Juli 1998, Poster/Abstract-Nr. 41222

Stroeer S, Jäger H, Hammel G, Wolf E, Knechten H, Schloer St. Comparison of three commercial kits for quantification of HIV-1-RNA in an open, prospective study in Germany (ART 96). 12th World AIDS Conference Genf, 28. Juni - 3. Juli 1998, Abstract-Nr. 60504

Fuchs A, Wolf E, Scheider A, Kampik A, Jäger H. Significance of CD4 Cell Count and HIV Viral Load on CMV-Retinitis Treated With an Implant. 12th World AIDS Conference. Genf, 28. Juni - 3. Juli 1998, Poster/Abstract-Nr. 32243

Ronel J, Mitzdorf U, Wolf E, Jägel-Guedes E, Jäger H. Psychosocial Factors Affect-ing the Progression of the HIV-Disease in Homosexual Men. 12th World AIDS Conference. Genf, 28. Juni - 3. Juli 1998, Poster/Abstract-Nr. 13340

Jäger H, Wolf E, Hammel G, Zwingers T, Graafmans J, Goetzenich A, Knechten H. HAART is not Hard Enough - Virological Failure after 12 months of Treatment in ART-Naive HIV+ Patients. 12th World AIDS Conference. Genf, 28. Juni - 3. Juli 1998, Poster/Abstract-Nr. 32319

Jägel-Guedes E, Wolf E, Virgin G, Pascucci R, Mauss S, Jäger H, D4T/ddI Plus Hy-droxyurea - An Alternative to a PI Containing Triple Regimen in ART-Naive HIV+ Patients? 12th World AIDS Conference. Genf, 28. Juni - 3. Juli 1998, Poster/ Abs-tract-Nr. 32315

Mauss S, Wolf E, Pascucci R, Virgin G, Jägel-Guedes E, Jäger H. Risk Factors For Diabetes Mellitus in HIV Positive Patients. 12th World AIDS Conference. Genf, 28. Juni - 3. Juli 1998, Poster/Abstract-Nr. 12377

Mauss S, Wolf E, Jägel-Guedes E, Pascucci R, Jäger H. Decreasing Incidence of Mycobacterial Diseases in HIV+ Patients. 12th World AIDS Conference. Genf, 28. Juni - 3. Juli 1998, Poster/Abstract-Nr. 22166

Pascucci R, Sonnenberg-Schwan U, Wolf E, Jägel-Guedes E, Jäger H. A Model of Care for HIV-Positive Pregnant Women. I Convegno Nazionale L’A.I.D.S: e la Donna, Neapel, 26. -28. März 1998, Poster/Abstract-Band S. 179

Wolf E, Zwingers T, Jäger H. AZT+3TC versus d4T+3TC in treatment naive HIV-patients. 6th European Conference on Clinical Aspects and Treatment of HIV In-fection. Hamburg, 11. - 15. Oktober 1997. Poster/Abstract Nr. 370.

Fuchs A, Wolf E, Scheider A, Jäger H, Klauß V, Kampik A. Ganciclovir-Implantat vs Systemic Therapy: CMV-Retinitis with AIDS. 2nd International Symposium on Ex-perimental and Clinical Ocular Pharmacology and Pharmaceutics. Berlin, 20. - 23. September 1997

Poppinger J, Wolf E, Jäger H. Viruslast und MAC Inzidenz. 6. Münchner AIDS-Tage, München, 4. - 6. Juli 1997. In: Jäger (Hrsg.). AIDS – Neue Perspektiven – Thera-peutische Erwartungen – Die Realität 1997. Ecomed Verlag, Landsberg/Lech 1997.

Virgin G, Jägel-Guedes E, Pascucci R, Poppinger J, Wolf E, Gorriahn D, Ryttig KR, Schiotz J, Jäger H. Tolerability, Immunostimulating and Antiviral Efficacy of the Peptide FR-91 in the Treatment of HIV Positive Patients. A Phase II Study. 6. Münchner AIDS-Tage. München, 4. - 6. Juli 1997. In: Jäger (Hrsg.). AIDS – Neue Perspektiven – Therapeutische Erwartungen – Die Realität 1997. Ecomed Verlag, Landsberg/Lech 1997.

Poppinger J, Wolf E, Pascucci R, Jägel-Guedes E, Jäger H. Cortison in der HIV The-rapie. 6. Münchner AIDS-Tage. München, 4. - 6. Juli 1997. In: Jäger (Hrsg.). AIDS – Neue Perspektiven – Therapeutische Erwartungen – Die Realität 1997. Ecomed Verlag, Landsber/Lech 1997.

Wolf E, Gersbacher E, Poppinger J, Virgin G, Pascucci R, Jägel-Guedes E, Jäger H. CMV Infection - A Systemic Clinical Disease? 4th Conference on Retroviruses and Opportunistic Infections. Washington, 22. - 26. Januar 1997.

Pascucci Rita, Wolf E, Virgin G, Poppinger J, Jäger H. Community Based Oberser-vations Support Virostatic Efficacy of d4T in Advanced HIV-Patients. XI. Interna-tional Conference on AIDS. Vancouver, Kanada, 7. - 12. Juli 1996. Poster/Abstract Nr. We.B.3120.

Popescu M, Wolf E, Jägel-Guedes E, Jäger H. HIV-1 RNA Viral Load Measure-ments. Are they a Good Predictor of Mortality in CDC-AIDS-Patients? XI. Interna-tional Conference on AIDS. Vancouver, Kanada, 7. - 12. Juli 1996. Th.B. 4298.

Wolf E, Virgin G, Dietrich U, Immelmann A, Jägel-Guedes E, Jäger H, Poppinger J. The Impact of Genotype Drug Resistance on Viral Burden. XI. International Con-ference on AIDS. Vancouver, Kanada, 7. - 12. Juli 1996. Poster/Abstract Nr. Th.B.4343.

Glaessel F, Wolf E, Buschmans E, Stauder G, Poppinger J, Jägel-Guedes E, Jäger H. Efficacy and Toxicity of Hydrolytic Enzymes in the Treatment of HIV Infection. XI. International Conference on AIDS. Vancouver, Kanada, 7. - 12. Juli 1996. Poster/Abstract Nr. Th.B.4100.

Virgin G, Wolf E, Zander K, v. Steinbuechl N, Gorriahn D, Bauer G, Albrecht H, Pop-pinger J, Jägel-Guedes E, Jäger H. Efficacy of Peptide T in the Palliative Treat-ment of HIV Related Symptoms. XI. International Conference on AIDS. Vancou-ver, Kanada, 7. - 12. Juli 1996. Poster/Abstract Nr. Th.B.180.

Wildegger A, Maier O, Förtsch M, Wolf E, Virgin G, Jäger H. Sample Transportation on Blue Instead of Dry Ice - The Impact on Plasma HIV-1 RNA Stability. XI. Inter-national Conference on AIDS. Vancouver, Kanada, 7. - 12. Juli 1996. Poster/Abstract Nr. Th.B.4339.

Jägel-Guedes Eva, Pascucci R, Wolf E, Gorriahn D, Jäger H. Toxicity, Immunes-timulating and Antiretroviral Efficacy of the Peptide FR-91 in the Treatment of HIV Positive Patients. XI. International Conference on AIDS. Vancouver, Kanada, 7. - 12. Juli 1996

Jäger H, Virgin G, Pascucci R, Poppinger J, Jägel-Guedes E, Wolf E. Virostatic Effi-cacy of AZT+3TC in Advanced HIV Patients with Previous Exposure to Antiretrovi-ral Drugs - Community Based Data. XI. International Conference on AIDS. Van-couver, Kanada, 7. - 12. Juli 1996. Poster/Abstract Nr. We.B.3121.

Zink Th, Virgin G, Wolf E, Poppinger J, Jägel-Guedes E, Jäger H. High Self Re-ported Alcohol Consumption is Not Correlated With Shorter Life Expectancy in AIDS Patients. XI. International Conference on AIDS. Vancouver, Kanada, 7. - 12. Juli 1996. Poster/Abstract Nr. Th.B.4280.

Woelken Michael, Poppinger J, Wolf E, Jägel-Guedes E, Jäger H. Oral Retarded Morphine in Pain Management in HIV Patients. XI. International Conference on AIDS. Vancouver, Kanada, 7. - 12. Juli 1996. Poster/Abstract Nr. Th.B.4115.

Poppinger J, Wolf E, Virgin G, Jägel-Guedes E, Jäger H. Impact of Palliative Corti-coid Therapy in Advanced HIV-1-RNA in Plasma. XI. International Conference on AIDS, Vancouver. Kanada, 7. - 12. Juli 1996. Poster/Abstract Nr. Th.B.195.

Ruppach H, Knechten H, Knickmann M, Jäger H, Jägel-Guedes E, Wolf E, Rübsa-men-Waigmann H, Dietrich H. Hinweise für eine Veränderung der HIV-Epidemie in westlichen Ländern: Zunahme der HIV-1 Subtypen E und C unter den HIV-1 Neuinfektionen in Deutschland. 5. Münchner AIDS-Tage. München, 26.- 28. Ja-nuar 1996. In: Jäger (Hrsg.). AIDS und HIV-Infektionen in Klinik und Praxis – Ma-nagement der Erkrankung. Ecomed Verlag, Landsberg/Lech 1996.

Poppinger J, Wolf E, Jägel-Guedes E, Jäger H. Klinische Diagnostik der MAC - Er-fahrungen in einer HIV-Schwerpunktpraxis. 5. Münchner AIDS-Tage. Mün-chen,26.- 28. Januar 1996. In: Jäger (Hrsg.). AIDS und HIV-Infektionen in Klinik und Praxis – Management der Erkrankung. Ecomed Verlag, Landsberg/Lech 1996.

Schlenzig C, Poppinger J, Wolf E, Jäger H. Efficacy and Toxicity of ddI and AZT Monotherapy Versus Combined and Alternating AZT/ddI Regimes. X. International Conference on AIDS. Yokohama, Japan, 7. - 12. August 1994. PBO261.

Wolf E, Hartl H, Poppinger J, Jägel-Guedes E, Jäger H. G-CSF Given to Severly Ill Patients in a Community-based Setting. Filgastrim Improves White Blood Cell Counts in HIV-Related Granulocytopenia - No Lasting Decline in Thrombocytes. IX. International Conference on AIDS. Berlin, Juni 1993. Poster/Abstract Nr. PO-B32-2246.

Jägel-Guedes E, Schmuck B, Poppinger J, Wolf E, Jäger H. How Much Does It Cost? A Clinicians View of Drug Expenses in HIV-Disease. IX. International Con-ference on AIDS. Berlin, Juni 1993. Poster/Abstract Nr. PO-D28-4214